Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 43,198 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 43,198 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $0.55, for a total transaction of $23,758.90. Following the completion of the transaction, the director owned 2,266,671 shares in the company, valued at $1,246,669.05. The trade was a 1.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Luke Evnin also recently made the following trade(s):

• On Thursday, January 15th, Luke Evnin sold 37,413 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.55, for a total transaction of $20,577.15.
• On Wednesday, January 14th, Luke Evnin sold 30,616 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total value of $17,451.12.
• On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total value of $33,618.60.
• On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $15,053.58.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total value of $15,476.44.

Werewolf Therapeutics Stock Down 5.7%

HOWL stock opened at $0.55 on Friday. The stock has a market capitalization of $26.74 million, a P/E ratio of -0.34 and a beta of 0.77. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. Werewolf Therapeutics, Inc. has a 1-year low of $0.53 and a 1-year high of $2.38. The business has a fifty day moving average price of $0.84 and a 200-day moving average price of $1.23.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03. Equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds have recently made changes to their positions in the company. Y Intercept Hong Kong Ltd bought a new stake in Werewolf Therapeutics in the 2nd quarter worth approximately $92,000. Susquehanna International Group LLP grew its holdings in shares of Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares in the last quarter. Citadel Advisors LLC bought a new stake in Werewolf Therapeutics in the third quarter worth $304,000. Vanguard Group Inc. increased its position in Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares in the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on HOWL shares. Wedbush downgraded shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 target price for the company. in a research report on Friday, December 19th. HC Wainwright dropped their price target on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 19th. Bank of America reduced their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Citizens Jmp downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Werewolf Therapeutics currently has a consensus rating of “Hold” and an average price target of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.